CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenue:
Total revenue	$ 10,460	$ 21,639
Operating costs and expenses:
Cost of goods sold	0	8,534
Research and development (including $208 and $0, respectively, from a related party)	30,480	27,408
General and administrative	24,346	20,149
Restructuring and impairment	169	975
Total operating costs and expenses	54,995	57,066
Loss from operations	(44,535)	(35,427)
Non-operating income (expense):
Non-cash interest expense on liabilities related to the sales of future royalties	(4,974)	(5,531)
Interest income	2,874	4,220
Other income (expense), net	266	(99)
Total non-operating income (expense), net	(1,834)	(1,410)
Loss before provision (benefit) for income taxes and equity method investment	(46,369)	(36,837)
Provision (benefit) for income taxes	52	(35)
Loss before equity method investment	(46,421)	(36,802)
Loss from equity method investment	(4,461)	0
Net loss	$ (50,882)	$ (36,802)
Basic net loss per share (in dollars per share)	$ (0.24)	$ (0.19)
Diluted net loss per share (in dollars per share)	$ (0.24)	$ (0.19)
Weighted average shares outstanding used in computing basic net loss per share (in shares)	210,924	194,746
Weighted average shares outstanding used in computing diluted net loss per share (in shares)	210,924	194,746
Product sales
Revenue:
Total revenue	$ 0	$ 6,034
Non-cash royalty revenue related to the sales of future royalties
Revenue:
Total revenue	10,460	15,508
License, collaboration and other revenue
Revenue:
Total revenue	$ 0	$ 97